Q-omics provides the consensus-scored RPS2P17 profile across patient tissues and cancer cell-line models. RPS2P17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS2P17 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPS2P17 RNA expression shows 14,572 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where RPS2P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS2P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS2P17 survival associations across molecular data types. RPS2P17 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS2P17 RNA expression–survival associations across cancer types. High RPS2P17 expression shows unfavorable associations in KIRP, ACC and LGG, but favorable associations in THCA, CESC and GBM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS2P17 RNA expression.
This table summarizes RPS2P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS2P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS2P17 shows higher tumor expression in KIRC, COAD, KIRP, LUAD, LUSC and LIHC. The KIRC box plot shows higher RPS2P17 RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with RPS2P17 in patient tissues and cancer cell lines. In patient samples, RPS2P17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
